TW202330589A - 治療 - Google Patents

治療 Download PDF

Info

Publication number
TW202330589A
TW202330589A TW111146224A TW111146224A TW202330589A TW 202330589 A TW202330589 A TW 202330589A TW 111146224 A TW111146224 A TW 111146224A TW 111146224 A TW111146224 A TW 111146224A TW 202330589 A TW202330589 A TW 202330589A
Authority
TW
Taiwan
Prior art keywords
dose
tcr
range
fusion molecule
amino acid
Prior art date
Application number
TW111146224A
Other languages
English (en)
Chinese (zh)
Inventor
穆罕默德 達爾
夏農 馬歇爾
夏德 阿卜杜拉
Original Assignee
英商英美偌科有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商英美偌科有限公司 filed Critical 英商英美偌科有限公司
Publication of TW202330589A publication Critical patent/TW202330589A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
TW111146224A 2021-12-01 2022-12-01 治療 TW202330589A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163285044P 2021-12-01 2021-12-01
US63/285,044 2021-12-01
US202263374222P 2022-08-31 2022-08-31
US63/374,222 2022-08-31

Publications (1)

Publication Number Publication Date
TW202330589A true TW202330589A (zh) 2023-08-01

Family

ID=84688213

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111146224A TW202330589A (zh) 2021-12-01 2022-12-01 治療

Country Status (9)

Country Link
US (1) US20250333504A1 (cg-RX-API-DMAC10.html)
EP (1) EP4441096A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024542682A (cg-RX-API-DMAC10.html)
KR (1) KR20240114759A (cg-RX-API-DMAC10.html)
AU (1) AU2022402322A1 (cg-RX-API-DMAC10.html)
IL (1) IL312981A (cg-RX-API-DMAC10.html)
MX (1) MX2024006799A (cg-RX-API-DMAC10.html)
TW (1) TW202330589A (cg-RX-API-DMAC10.html)
WO (1) WO2023099622A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202519257A (zh) 2023-08-01 2025-05-16 英商英美偌科有限公司 治療皮膚黑色素瘤之方法
TW202544042A (zh) 2024-03-13 2025-11-16 英商英美偌科有限公司 治療prame陽性癌症之方法
WO2025224692A1 (en) 2024-04-25 2025-10-30 Immunocore Limited Method of treating cancer using a gene expression signature

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
JP7599819B2 (ja) * 2016-06-02 2024-12-16 イムノコア リミテッド gp100特異的TCR-抗CD3 scFv融合タンパク質の投薬レジメン
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
JP2024542682A (ja) 2024-11-15
WO2023099622A1 (en) 2023-06-08
IL312981A (en) 2024-07-01
AU2022402322A1 (en) 2024-06-20
KR20240114759A (ko) 2024-07-24
MX2024006799A (es) 2024-08-22
US20250333504A1 (en) 2025-10-30
EP4441096A1 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
US20250333504A1 (en) Treatment
TWI795347B (zh) 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
KR20230117120A (ko) 인터류킨-18 변이체 및 사용 방법
TW202035440A (zh) 新穎合理設計的蛋白質組合物
US20240301027A1 (en) Treatment of mage-a4 positive cancer
CN111148756A (zh) T细胞受体
Azadi et al. Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines
WO2023081718A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
KR20180138205A (ko) 항-lgr5 단클론성 항체의 투여
JP7850365B2 (ja) Lgr5及びegfrに結合する抗体によるがんの治療
JP2026514110A (ja) がんの処置および予防のための組合せ
CA3239837A1 (en) Treatment
TW202440154A (zh) 用pd-1軸結合拮抗劑及rna疫苗治療胰臟癌之方法
CN118510808A (zh) 治疗
WO2013170779A1 (zh) 一种含有抗vegf抗体的药物组合物
WO2008037225A1 (es) Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
WO2016163433A1 (ja) 抗fgfr2抗体と他剤を含む組成物
WO2025027557A1 (en) Method of treating cutaneous melanoma
HK40098919A (en) Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
TW202332698A (zh) 癌症之組合療法
JP2025540235A (ja) がんの処置および予防のための組合せ
HK40100300A (en) Interleukin-18 variants and methods of use
HK40107230A (en) Therapeutic and diagnostic methods and compositions for cancer